{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T22:45:59Z","timestamp":1778280359017,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"DOI":"10.1038\/s41746-024-01323-1","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T19:41:47Z","timestamp":1731181307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Post-marketing surveillance of anticancer drugs using natural language processing of electronic medical records"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7277-0827","authenticated-orcid":false,"given":"Yoshimasa","family":"Kawazoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiminori","family":"Shimamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohisa","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3846-0435","authenticated-orcid":false,"given":"Masami","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiko","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6209-1054","authenticated-orcid":false,"given":"Shuntaro","family":"Yada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Wakamiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shungo","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4596-5418","authenticated-orcid":false,"given":"Satoko","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Aramaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"1323_CR1","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1185\/030079905X41426","volume":"21","author":"S Gough","year":"2005","unstructured":"Gough, S. Post-marketing surveillance: a UK\/European perspective. Curr. Med. Res. Opin. 21, 565\u2013570 (2005).","journal-title":"Curr. Med. Res. Opin."},{"key":"1323_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. & Shakir, S. A. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29, 385\u2013396 (2006).","journal-title":"Drug Saf."},{"key":"1323_CR3","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar, M., Tawfiq, A. M., Hassan, N. & Palaian, S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther. Adv. Drug Saf. 11, 2042098620938595 (2020).","journal-title":"Ther. Adv. Drug Saf."},{"key":"1323_CR4","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s11096-023-01592-y","volume":"45","author":"C Costa","year":"2023","unstructured":"Costa, C. et al. Factors associated with underreporting of adverse drug reactions by patients: a systematic review. Int. J. Clin. Pharm. 45, 1349\u20131358 (2023).","journal-title":"Int. J. Clin. Pharm."},{"key":"1323_CR5","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMp0905338","volume":"361","author":"R Platt","year":"2009","unstructured":"Platt, R. et al. The new Sentinel Network-improving the evidence of medical-product safety. N. Engl. J. Med. 361, 645\u2013647 (2009).","journal-title":"N. Engl. J. Med."},{"key":"1323_CR6","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pds.4879","volume":"28","author":"M Yamaguchi","year":"2019","unstructured":"Yamaguchi, M. et al. Establishment of the MID-NET\u00ae medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol. Drug Saf. 28, 1395\u20131404 (2019).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"1323_CR7","unstructured":"Sentinel Common Data Model. https:\/\/www.sentinelinitiative.org\/methods-data-tools\/sentinel-common-data-model (2024)."},{"key":"1323_CR8","unstructured":"Current status and practices of quality management for MID-NET. https:\/\/www.pmda.go.jp\/files\/000244339.pdf (2019)."},{"key":"1323_CR9","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jamia.2010.008607","volume":"17","author":"PM Nadkarni","year":"2010","unstructured":"Nadkarni, P. M. Drug safety surveillance using de-identified EMR and claims data: issues and challenges. J. Am. Med. Inform. Assoc. 17, 671\u2013674 (2010).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1323_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1377\/hlthaff.2011.0190","volume":"30","author":"DC Classen","year":"2011","unstructured":"Classen, D. C. et al. Global trigger tool\u2019 shows that adverse events in hospitals may be ten times greater than previously measured. Health Aff. 30, 581\u2013589 (2011).","journal-title":"Health Aff."},{"key":"1323_CR11","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1007\/s40264-017-0558-6","volume":"40","author":"Y Luo","year":"2017","unstructured":"Luo, Y. et al. Natural Language Processing for EHR-Based Pharmacovigilance: a structured review. Drug Saf. 40, 1075\u20131089 (2017).","journal-title":"Drug Saf."},{"key":"1323_CR12","doi-asserted-by":"publisher","first-page":"104621","DOI":"10.1016\/j.jbi.2024.104621","volume":"152","author":"Y Li","year":"2024","unstructured":"Li, Y. et al. Artificial intelligence-powered pharmacovigilance: a review of machine and deep learning in clinical text-based adverse drug event detection for benchmark datasets. J. Biomed. Inform. 152, 104621 (2024).","journal-title":"J. Biomed. Inform."},{"key":"1323_CR13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41746-022-00590-0","volume":"5","author":"S Khurshid","year":"2022","unstructured":"Khurshid, S. et al. Cohort design and natural language processing to reduce bias in electronic health records research. NPJ Digit. Med. 5, 47 (2022).","journal-title":"NPJ Digit. Med."},{"key":"1323_CR14","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41746-023-00817-8","volume":"6","author":"Y Sheu","year":"2023","unstructured":"Sheu, Y. et al. AI-assisted prediction of differential response to antidepressant classes using electronic health records. NPJ Digit. Med. 6, 73 (2023).","journal-title":"NPJ Digit. Med."},{"key":"1323_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41746-024-01120-w","volume":"7","author":"HJ Lee","year":"2024","unstructured":"Lee, H. J. et al. StrokeClassifier: ischemic stroke etiology classification by ensemble consensus modeling using electronic health records. NPJ Digit. Med. 7, 130 (2024).","journal-title":"NPJ Digit. Med."},{"key":"1323_CR16","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41746-023-00970-0","volume":"7","author":"M Guevara","year":"2024","unstructured":"Guevara, M. et al. Large language models to identify social determinants of health in electronic health records. NPJ Digit. Med. 7, 6 (2024).","journal-title":"NPJ Digit. Med."},{"key":"1323_CR17","unstructured":"Devlin, J., Chang, M.-W., Lee, K. & Toutanova, K. BERT: Pre-training of deep bidirectional transformers for language understanding. In Proc. 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers), 4171\u20134186. (Association for Computational Linguistics, 2019)."},{"key":"1323_CR18","first-page":"5998","volume":"30","author":"A Vaswani","year":"2017","unstructured":"Vaswani, A. et al. Attention is all you need. Adv. Neural Inf. Process. Syst. 30, 5998\u20136008 (2017).","journal-title":"Adv. Neural Inf. Process. Syst."},{"key":"1323_CR19","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/bioinformatics\/btz682","volume":"36","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics 36, 1234\u20131240 (2020).","journal-title":"Bioinformatics"},{"key":"1323_CR20","doi-asserted-by":"publisher","first-page":"e0259763","DOI":"10.1371\/journal.pone.0259763","volume":"16","author":"Y Kawazoe","year":"2021","unstructured":"Kawazoe, Y., Shibata, D., Shinohara, E., Aramaki, E. & Ohe, K. A clinical specific BERT developed using a huge Japanese clinical text corpus. PLoS One 16, e0259763 (2021).","journal-title":"PLoS One"},{"key":"1323_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-17806-8","volume":"12","author":"Y Kim","year":"2022","unstructured":"Kim, Y. et al. A pre-trained BERT for Korean medical natural language processing. Sci. Rep. 12, 13847 (2022).","journal-title":"Sci. Rep."},{"key":"1323_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-018-0687-6","volume":"18","author":"S Zhou","year":"2018","unstructured":"Zhou, S., Kang, H., Yao, B. & Gong, Y. An automated pipeline for analyzing medication event reports in clinical settings. BMC Med. Inform. Decis. Mak. 18, 113 (2018).","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"1323_CR23","doi-asserted-by":"publisher","first-page":"102473","DOI":"10.1016\/j.ipm.2020.102473","volume":"58","author":"E El-allaly","year":"2021","unstructured":"El-allaly, E., Sarrouti, M., En-Nahnahi, N. & Ouatik El Alaoui, S. MTTLADE: a multi-task transfer learning-based method for adverse drug events extraction. Inf. Process Manag. 58, 102473 (2021).","journal-title":"Inf. Process Manag."},{"key":"1323_CR24","first-page":"420","volume":"2021","author":"D Mahendran","year":"2021","unstructured":"Mahendran, D. & McInnes, B. T. Extracting adverse drug events from clinical notes. AMIA Jt Summits Transl. Sci. Proc. 2021, 420\u2013429 (2021).","journal-title":"AMIA Jt Summits Transl. Sci. Proc."},{"key":"1323_CR25","doi-asserted-by":"publisher","DOI":"10.2196\/26407","volume":"9","author":"H Wu","year":"2021","unstructured":"Wu, H. et al. Chinese-named entity recognition from adverse drug event records: radical embedding-combined dynamic embedding-based BERT in a Bidirectional Long Short-term Conditional Random Field (Bi-LSTM-CRF) model. JMIR Med. Inform. 9, e26407 (2021).","journal-title":"JMIR Med. Inform."},{"key":"1323_CR26","doi-asserted-by":"publisher","first-page":"103960","DOI":"10.1016\/j.jbi.2021.103960","volume":"125","author":"S Narayanan","year":"2022","unstructured":"Narayanan, S. et al. A contextual multi-task neural approach to medication and adverse events identification from clinical text. J. Biomed. Inform. 125, 103960 (2022).","journal-title":"J. Biomed. Inform."},{"key":"1323_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40264-023-01323-2","volume":"46","author":"S Kim","year":"2023","unstructured":"Kim, S. et al. Automatic extraction of comprehensive drug safety information from adverse drug event narratives in the Korea adverse event reporting system using natural language processing techniques. Drug. Saf. 46, 781\u2013795 (2023).","journal-title":"Drug. Saf."},{"key":"1323_CR28","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1039\/C8DT00838H","volume":"47","author":"R Oun","year":"2018","unstructured":"Oun, R., Moussa, Y. E. & Wheate, N. J. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans. 47, 6645\u20136653 (2018).","journal-title":"Dalton Trans."},{"key":"1323_CR29","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10120-020-01101-4","volume":"24","author":"KW Lee","year":"2021","unstructured":"Lee, K. W. et al. SOPP study investigators. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer 24, 156\u2013167 (2021).","journal-title":"Gastric Cancer"},{"key":"1323_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","volume":"9","author":"J Burgess","year":"2021","unstructured":"Burgess, J. et al. Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment. Oncol. Ther. 9, 385\u2013450 (2021).","journal-title":"Oncol. Ther."},{"key":"1323_CR31","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1007\/s00520-014-2317-x","volume":"22","author":"CM Bridges","year":"2014","unstructured":"Bridges, C. M. & Smith, E. M. What about Alice? Peripheral neuropathy from taxane-containing treatment for advanced nonsmall cell lung cancer. Support Care Cancer 22, 2581\u20132592 (2014).","journal-title":"Support Care Cancer"},{"key":"1323_CR32","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka, S. et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J. Clin. Oncol. 31, 4438\u20134444 (2013).","journal-title":"J. Clin. Oncol."},{"key":"1323_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1097\/00000421-199806000-00008","volume":"21","author":"ME Stein","year":"1988","unstructured":"Stein, M. E. et al. A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients. Am. J. Clin. Oncol. 21, 248\u2013249 (1988).","journal-title":"Am. J. Clin. Oncol."},{"key":"1323_CR34","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/00001813-200107000-00006","volume":"12","author":"MW Saif","year":"2001","unstructured":"Saif, M. W. et al. Peripheral neuropathy associated with weekly oral 5-fluorouracil, leucovorin and eniluracil. Anticancer Drugs 12, 525\u2013531 (2001).","journal-title":"Anticancer Drugs"},{"key":"1323_CR35","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1593\/neo.04169","volume":"6","author":"MU Naidu","year":"2004","unstructured":"Naidu, M. U. et al. Chemotherapy-induced and\/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia 6, 423\u2013431 (2004).","journal-title":"Neoplasia"},{"key":"1323_CR36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0167-8140(02)00404-8","volume":"66","author":"A Trotti","year":"2003","unstructured":"Trotti, A. et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother. Oncol. 66, 253\u2013262 (2003).","journal-title":"Radiother. Oncol."},{"key":"1323_CR37","doi-asserted-by":"publisher","first-page":"5542","DOI":"10.1200\/JCO.2005.02.027","volume":"23","author":"SE Jones","year":"2005","unstructured":"Jones, S. E. et al. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23, 5542\u20135551 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1323_CR38","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/S1470-2045(17)30622-8","volume":"18","author":"B Seddon","year":"2017","unstructured":"Seddon, B. et al. Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomized controlled phase 3 trial. Lancet Oncol. 18, 1397\u20131410 (2017).","journal-title":"Lancet Oncol."},{"key":"1323_CR39","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1200\/JCO.1999.17.8.2412","volume":"17","author":"RA Popescu","year":"1999","unstructured":"Popescu, R. A., Norman, A., Ross, P. J., Parikh, B. & Cunningham, D. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J. Clin. Oncol. 17, 2412\u20132418 (1999).","journal-title":"J. Clin. Oncol."},{"key":"1323_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1517\/14740338.2016.1105959","volume":"15","author":"O Abdel-Rahman","year":"2016","unstructured":"Abdel-Rahman, O., ElHalawani, H. & Essam-Eldin, S. S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines. Expert Opin. Drug Saf. 15, 5\u201320 (2016).","journal-title":"Expert Opin. Drug Saf."},{"key":"1323_CR41","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1634\/theoncologist.2009-0333","volume":"15","author":"A Zabernigg","year":"2010","unstructured":"Zabernigg, A. et al. Taste alterations in cancer patients receiving chemotherapy: a neglected side effect? Oncologist 15, 913\u2013920 (2010).","journal-title":"Oncologist"},{"key":"1323_CR42","first-page":"697","volume":"26","author":"RS Wickham","year":"1999","unstructured":"Wickham, R. S. et al. Taste changes experienced by patients receiving chemotherapy. Oncol. Nurs. Forum 26, 697\u2013706 (1999).","journal-title":"Oncol. Nurs. Forum"},{"key":"1323_CR43","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1200\/JCO.2008.19.2690","volume":"27","author":"S Steinbach","year":"2009","unstructured":"Steinbach, S. et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J. Clin. Oncol. 27, 1899\u20131905 (2009).","journal-title":"J. Clin. Oncol."},{"key":"1323_CR44","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.3390\/ijms24032538","volume":"24","author":"T Buttiron Webber","year":"2023","unstructured":"Buttiron Webber, T., Briata, I. M., DeCensi, A., Cevasco, I. & Paleari, L. Taste and Smell Disorders in Cancer Treatment: Results from an Integrative Rapid Systematic Review. Int. J. Mol. Sci. 24, 2538 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1323_CR45","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1093\/annonc\/mdz402","volume":"30","author":"C Morizane","year":"2019","unstructured":"Morizane, C. et al. Members of the Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Ann. Oncol. 30, 1950\u20131958 (2019).","journal-title":"Ann. Oncol."},{"key":"1323_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.ctrv.2008.01.003","volume":"34","author":"AA Argyriou","year":"2008","unstructured":"Argyriou, A. A., Polychronopoulos, P., Iconomou, G., Chroni, E. & Kalofonos, H. P. A review on oxaliplatin-induced peripheral nerve damage. Cancer Treat. Rev. 34, 368\u2013377 (2008).","journal-title":"Cancer Treat. Rev."},{"key":"1323_CR47","doi-asserted-by":"publisher","first-page":"ooad111","DOI":"10.1093\/jamiaopen\/ooad111","volume":"6","author":"Z Lan","year":"2023","unstructured":"Lan, Z. & Turchin, A. Impact of possible errors in natural language processing-derived data on downstream epidemiologic analysis. JAMIA Open 6, ooad111 (2023).","journal-title":"JAMIA Open"},{"key":"1323_CR48","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1093\/jamia\/ocad259","volume":"31","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Improving large language models for clinical named entity recognition via prompt engineering. J. Am. Med. Inform. Assoc. 31, 1812\u20131820 (2024).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"1323_CR49","doi-asserted-by":"crossref","unstructured":"Soroush, A. et al. Large Language Models Are Poor Medical Coders\u2014Benchmarking of Medical Code Querying. NEJM AI. 1, AIdbp2300040 (2024).","DOI":"10.1056\/AIdbp2300040"},{"key":"1323_CR50","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli, M. et al. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf. 47, 585\u2013599 (2024).","journal-title":"Drug Saf."},{"key":"1323_CR51","doi-asserted-by":"publisher","first-page":"112744","DOI":"10.1016\/j.biopha.2022.112744","volume":"148","author":"Y Zamami","year":"2022","unstructured":"Zamami, Y. et al. Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. Biomed. Pharmacother. 148, 112744 (2022).","journal-title":"Biomed. Pharmacother."},{"key":"1323_CR52","doi-asserted-by":"publisher","first-page":"3241","DOI":"10.1111\/bcp.15252","volume":"88","author":"S Imai","year":"2022","unstructured":"Imai, S. et al. Using Japanese big data to investigate novel factors and their high-risk combinations that affect vancomycin-induced nephrotoxicity. Br. J. Clin. Pharmacol. 88, 3241\u20133255 (2022).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"1323_CR53","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1536\/ihj.46.855","volume":"46","author":"H Yasunaga","year":"2005","unstructured":"Yasunaga, H., Ide, H., Imamura, T. & Ohe, K. Impact of the Japanese Diagnosis Procedure Combination-based Payment System on cardiovascular medicine-related costs. Int. Heart J. 46, 855\u2013866 (2005).","journal-title":"Int. Heart J."},{"key":"1323_CR54","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.je.2016.09.009","volume":"27","author":"H Yamana","year":"2017","unstructured":"Yamana, H. et al. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J. Epidemiol. 27, 476\u2013482 (2017).","journal-title":"J. Epidemiol."},{"key":"1323_CR55","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1192\/bjp.bp.114.156265","volume":"208","author":"H Ishikawa","year":"2016","unstructured":"Ishikawa, H., Yasunaga, H., Matsui, H., Fushimi, K. & Kawakami, N. Differences in cancer stage, treatment and in-hospital mortality between patients with and without schizophrenia: retrospective matched-pair cohort study. Br. J. Psychiatry 208, 239\u2013244 (2016).","journal-title":"Br. J. Psychiatry"},{"key":"1323_CR56","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1097\/CCM.0000000000000943","volume":"43","author":"Y Sasabuchi","year":"2015","unstructured":"Sasabuchi, Y. et al. The volume-outcome relationship in critically Ill patients in relation to the ICU-to-hospital bed ratio. Crit. Care Med. 43, 1239\u20131245 (2015).","journal-title":"Crit. Care Med."},{"key":"1323_CR57","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.jclinepi.2014.12.004","volume":"68","author":"H Yamana","year":"2015","unstructured":"Yamana, H., Matsui, H., Sasabuchi, Y., Fushimi, K. & Yasunaga, H. Categorized diagnoses and procedure records in an administrative database improved mortality prediction. J. Clin. Epidemiol. 68, 1028\u20131035 (2015).","journal-title":"J. Clin. Epidemiol."},{"key":"1323_CR58","doi-asserted-by":"publisher","unstructured":"Yada, S., Nakamura, Y., Wakamiya, S. & Aramaki, E. Cross-lingual natural language processing on limited annotated case\/radiology reports in English and Japanese: Insights from the Real-MedNLP workshop. Methods Inf. Med. (2024). https:\/\/doi.org\/10.1055\/a-2405-2489","DOI":"10.1055\/a-2405-2489"},{"key":"1323_CR59","unstructured":"tohoku-nlp\/bert-base-japanese-whole-word-masking. https:\/\/huggingface.co\/tohoku-nlp\/bert-base-japanese-whole-word-masking (2020)."},{"key":"1323_CR60","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/00031305.1985.10479383","volume":"39","author":"PR Rosenbaum","year":"1985","unstructured":"Rosenbaum, P. R. & Rubin, D. B. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am. Stat. 39, 33\u201338 (1985).","journal-title":"Am. Stat."},{"key":"1323_CR61","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"1323_CR62","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/mpr.329","volume":"20","author":"MJ Azur","year":"2011","unstructured":"Azur, M. J. et al. Multiple imputation by chained equations: what is it and how does it work? Int. J. Methods Psychiatr. Res. 20, 40\u201349 (2011).","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"1323_CR63","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada, Y. et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-na\u00efve patients with advanced gastric cancer. Ann. Oncol. 26, 141\u2013148 (2015).","journal-title":"Ann. Oncol."},{"key":"1323_CR64","doi-asserted-by":"publisher","first-page":"940239","DOI":"10.3389\/fonc.2022.940239","volume":"12","author":"JI Lai","year":"2022","unstructured":"Lai, J. I., Chao, T. C., Liu, C. Y., Huang, C. C. & Tseng, L. M. A systemic review of taxanes and their side effects in metastatic breast cancer. Front. Oncol. 12, 940239 (2022).","journal-title":"Front. Oncol."},{"key":"1323_CR65","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1002\/sim.2059","volume":"24","author":"R Bender","year":"2015","unstructured":"Bender, R., Augustin, T. & Blettner, M. Generating survival times to simulate Cox proportional hazards models. Stat. Med. 24, 1713\u20131723 (2015).","journal-title":"Stat. Med."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01323-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T21:21:21Z","timestamp":1731187281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-024-01323-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1323"],"URL":"https:\/\/doi.org\/10.1038\/s41746-024-01323-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"24 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.K., K.S., and E.S. belong to the Artificial Intelligence and Digital Twin in Healthcare, Graduate School of Medicine, University of Tokyo, which is an endowment department, and was supported by an unrestricted grant from EM Systems, EPNextS, MRP CO., LTD., SHIP HEALTHCARE HOLDINGS, INC., SoftBank Corp., and NEC Corporation; these organizations had no control over the interpretation, writing, or publication of this work. The other authors declare no financial or non-financial competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"315"}}